Modern principles of pharmacotherapy of chronic venous diseases
V.Yu. Bogachev, V.B. Boldin, S.V. Rodionov

Pirogov Russian National Research Medical University, Moscow

At the 19th annual congress of the European Venous Forum, which was held in Athens in June 28–30, 2018, the long-awaited updated recommendations on the diagnosis and treatment of chronic venous diseases (CVD) were presented, the full text of which can be found in the June issue of the International Angiology publication. This publication aims to familiarize the practitioners with one of the key sections of the new European recommendations on pharmacotherapy for CVD. The primary agents of medical treatment of CVD remain venoactive drugs (phleboprotectors). Along with the venoactive drugs, pentoxifylline and sulodexide are widely used in the pharmacotherapy of venous trophic ulcers. In recent years, a personalized approach has been approved to treating a particular patient and optimizing the choice of a pharmacological drug, depending on the presence of specific symptoms and syndromes. For this purpose, an NNT (number-needed-to-treat) indicator is used — the number of patients who need to be treated to obtain a positive result in one patient. Thus, the ideal NNT should be equal to one. Modern and adequate phlebotropic therapy, taking into account new recommendations at all stages of the pathological process from C0s to C6, regardless of the key pathogenetic mechanism — reflux or occlusion, expands our capabilities in control of CVD.

Key words: chronic venous diseases, pharmacotherapy, venoactive drugs.
For citation: Bogachev V.Yu., Boldin V.B., Rodionov S.V. Modern principles of pharmacotherapy of chronic venous diseases // 
RMJ. 2018. № 6(II). P. 74–79.